For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Price · 1Y
$22.22
Thesis
Legend Biotech co-commercializes CARVYKTI (cilta-cel) with Johnson & Johnson — the leading BCMA CAR-T for multiple myeloma, now moving into earlier lines of therapy where the addressable population is far larger. CARVYKTI's class-leading efficacy data have made it the share leader against Abecma, and capacity expansion is the gating factor on revenue.
The investment case is a commercial-stage cell-therapy leader with a blockbuster franchise and a J&J partnership underwriting reach. Risks: a China-rooted corporate structure that draws BIOSECURE-style political scrutiny, manufacturing-capacity constraints that have historically capped supply, and dependence on the single CARVYKTI franchise.
Catalysts
- CARVYKTI earlier-line expansion and revenue ramp
- Manufacturing-capacity additions
- Geopolitical / BIOSECURE policy developments
- Pipeline diversification beyond BCMA
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Jun 17Securities offeringSEC
Filed 424B5 prospectus supplement related to securities offering.